Breadcrumb

Azam Ghafoor, M.D.

Azam Ghafoor, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Associate Research Physician
Thoracic and GI Malignancies Branch
Head Thoracic Oncology Tumor Board

RESEARCH SUMMARY

Dr. Ghafoor's primary interests are studying early-onset cancers in healthy and cancer patients with predisposition syndrome such as BRACA1-Associated Protein-1 (BAP1). He is an expert in studying families and individual patients through radiographic imaging to determine the frequency and incidence of cancers as well as potential for early intervention.

Dr. Ghafoor is also a medical oncologist  in thoracic malignancies, where he treated patient with  mesothelioma and non-small cell lung cancer. His clinical research is focused on the use of anti-mesothelin therapies, including immunotoxins and CAR T tharpies against NSCLC and mesothelioma, and targeted therapies in comibination with local therapies for EGFR mutated NSCLC. His focus also includes optimizing immunotherapies and precision medicine for lung cancer patients using combination-based approaches to overcome and delay resistance.

Areas of Expertise

Early-onset Cancers
BAP1
CAR T-cell
Immunotherapy
Thoracic Cancers

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them.

Publications

Selected Recent Publications

Local Ablative Therapy followed by Osimertinib Rechallenge in Oligoprogressive, Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer: A Phase 2 study

Azam Ghafoor, MDa azam.ghafoor@nih.gov ∙ Nitin Roper, MDb ∙ Chul Kim, MD, MPHc ∙ Chuong D. Hoang, MDd ∙ Aparna H. Kesarwala, MD, PhDe,f ∙ Kevin A. Camphausen, MDf ∙ Kamran Farouq, BSa ∙ Elizabeth Akotha ∙ Corrine Keena ∙ Eva Szabo, MDa,g ∙ Hadi Bhageri, MDh ∙ Arun Rajan, MDa ∙ Udayan Guha, MD. PhD
JTO Clinical and Research Report. 2025.
Full-Text Article
[ Journal Article ]

Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results

Hassan R, Butler M, O'Cearbhaill RE, Oh DY, Johnson M, Zikaras K, Smalley M, Ross M, Tanyi JL, Ghafoor A, Shah NN, Saboury B, Cao L, Quintás-Cardama A, Hong D.
Nature Medicine. 2099-2109, 2023. [ Journal Article ]

Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene

Azam Ghafoor, Idrees Mian, Cathy Wagner, Yvonne Mallory, Maria Garcia Agra, Betsy Morrow, Jun S. Wei, Javed Khan, Anish Thomas, Manjistha Sengupta, Seth M. Steinberg, Raffit Hassan
JTO Clinical and Research Reports. Volume 2, Issue 10: 2021.
Full-Text Article

Orbital metastases from malignant mesothelioma

Idrees Mian, Emerson Padiernos, Raffit Hassan, Azam Ghafoor.
Lancet Oncology. 21(2): 117, 2020. [ Journal Article ]

Targeting mesothelin in ovarian cancer

Azam Ghafoor, Anish Thomas, and Raffit Hassan
Oncotarget. 9(90): 36050–36051, 2018. [ Journal Article ]